ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ½ÃÀåÁ¶»çº¸°í¼­

ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ½ÃÀåÀ» Á¶»ç ºÐ¼®ÇÑ ÀÚ·á·Î ½ÃÀå±Ô¸ð, »ê¾÷ºÐ¼®, ÇâÈÄ ½ÃÀå¿¹Ãø µîÀÇ ³»¿ëÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù.

1 - 25 (Àüü: 524°Ç)
¿À·º½Å ±æÇ×Á¦ ½ÃÀå º¸°í¼­ : µ¿Çâ, ¿¹Ãø, °æÀï ºÐ¼®(-2031³â)
Orexin Antagonist Market Report: Trends, Forecast and Competitive Analysis to 2031
¹ßÇà 2025³â 09¿ù
°¡°Ý US $ 3,850 £Ü 5,368,000 (ºÎ°¡¼¼ º°µµ)
ÀÎÅÍ·ùŲ-2 - ½ÃÀå ±Ô¸ð, Ç¥Àû Áý´Ü, °æÀï ±¸µµ, ½ÃÀå ¿¹Ãø(2034³â)
Interleukin-2-Market Size, Target Population, Competitive Landscape & Market Forecast - 2034
¹ßÇà 2025³â 09¿ù
°¡°Ý US $ 7,950 £Ü 11,084,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¸²ÇÁ°ü ±âÇü ½ÃÀå
Lymphatic Malformations
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
AI ±â¹Ý âÀǼº : Â÷º°È­ ¹× Âü¿©ÀÇ »õ·Î¿î ÁöÆò ¿­±â
AI-Powered Creativity: Unlocking New Frontiers of Differentiation and Engagement
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 7,500 £Ü 10,457,000 (ºÎ°¡¼¼ º°µµ)
±Û·çÄ«°ï ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : ÀûÀÀÁõº°, Åõ¿© °æ·Îº°, Á¦Á¦º°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - »ê¾÷ ¿¹Ãø(2025-2032³â)
Glucagon Market Size, Share, and Growth Analysis, By Indication (Hypoglycemia, Diabetic Ketoacidosis), By Route of Administration (Intravenous, Subcutaneous), By Formulation, By End-User, By Region - Industry Forecast 2025-2032
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,300 £Ü 7,389,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ CDKL5 °áÇÌÁõ(CDD) ½ÃÀå
CDKL5 Deficiency Disorder (CDD)
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ SGLT2 ¾ïÁ¦Á¦ ½ÃÀå : »ê¾÷±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø, ¾àÁ¦º°, ÀûÀÀÁõº°, Áö¿ªº°, °æÀﺰ(2020-2030³â)
SGLT2 Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug (Jardiance, Farmiga, Inpefa, Invokana, Others), By Indication (Type 2 Diabetes, Cardiovascular, Others), By Region and Competition, 2020-2030F
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 4,500 £Ü 6,274,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Æ®·ç¸®½ÃƼ ½ÃÀå
Trulicity
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ±¸°­Á¡¸·¿° Ä¡·á ½ÃÀå
Oral Mucositis Treatment
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Å¸¾×·ç Ä¡·á ½ÃÀå
Sialorrhea Treatment
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Áø¼ºÀûÇ÷±¸Áõ°¡Áõ Ä¡·áÁ¦ ½ÃÀå
Polycythemia Vera Drugs
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ºñ°áÇÙ¼ºÇ×»ê±ÕÁõ ½ÃÀå
Nontuberculous Mycobacterial Infections
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ´Ù°èÅë À§ÃàÁõ ½ÃÀå
Multiple System Atrophy
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Èí¼öºÒ·®ÁõÈıº ½ÃÀå
Malabsorption Syndrome
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¾î¼Å ÁõÈıº Ä¡·á ½ÃÀå
Usher Syndrome Treatment
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Àü½Å¼º ¼Ò¾ÆÆ¯¹ß¼º°üÀý¿° ½ÃÀå
Systemic Juvenile Idiopathic Arthritis
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ÀÌÁú±Õ °Ë»ç ŰƮ ½ÃÀå
Shigella Test Kits
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Å¥¿­ ½ÃÀå
Q Fever
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Æä´Ò¾Ë¶ó´Ñ ½ÃÀå
Phenylalanine
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ÀûÇ÷±¸Áõ°¡Áõ ½ÃÀå
Polycythemia
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ µ¿ÇüÁ¢ÇÕ °¡Á·¼º °íÄÝ·¹½ºÅ×·ÑÇ÷Áõ ½ÃÀå
Homozygous Familial Hypercholesterolemia
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ SGLT2 ¾ïÁ¦Á¦ ½ÃÀå
SGLT2 Inhibitors
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¸ÞÆ¿¾Ë·ç¹Ì³ì»ê MAO ½ÃÀå º¸°í¼­ : µ¿Çâ, ¿¹Ãø ¹× °æÀï ºÐ¼®(-2031³â)
Methylaluminoxane MAO Market Report: Trends, Forecast and Competitive Analysis to 2031
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 3,850 £Ü 5,368,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ µðÆéƼµô ÆéƼ´Ù¾ÆÁ¦ 4 ¾ïÁ¦Á¦ ½ÃÀå
Dipeptidyl Peptidase 4 Inhibitors
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¸»´Üºñ´ëÁõ Ä¡·á ½ÃÀå
Acromegaly Treatment
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,156,000 (ºÎ°¡¼¼ º°µµ)
(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.